<DOC>
	<DOCNO>NCT01883297</DOCNO>
	<brief_summary>This phase I clinical study patient platinum resistant ( respond platinum-based chemotherapy ) high grade serous ovarian , fallopian tube , primary peritoneal cancer . Prior main treatment , patient receive cyclophosphamide vein . Patients receive infusion ( give vein ) autologous tumor-infiltrating lymphocyte ( TILs ) first take patient , stimulate certain substance call autologous dendritic cell ( DCs ) OKT3 ( anti-CD3 antibody ) , give back patient infusion . This believe make TILs work well . TILs type white blood cell recognize tumor cell enter cause tumor cell break . After infusion TILs , low-dose interleukin-2 ( IL-2 ) therapy give .</brief_summary>
	<brief_title>`` Re-Stimulated '' Tumor-Infiltrating Lymphocytes And Low-Dose Interleukin-2 Therapy Patients With Platinum Resistant High Grade Serous Ovarian , Fallopian Tube , Primary Peritoneal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria ( Eligibility TIL Evaluation ) : 1 . Platinum resistant high grade serous ovarian , fallopian tube , primary peritoneal cancer . 2 . Tumor suitable harvest ( i.e. , lesion harvest TIL evaluation total volume ≥1cm3 ) patient previously undergone tumor harvest REB approve study involve clinical evaluation TILs . 3 . If tumor harvest require , subject must suitable surgical candidate opinion operate surgeon . 4 . Patient age : ≥ 18 year . 5 . Clinical performance status ECOG 0 1 . 6 . Life expectancy &gt; 5 month date consent TIL evaluation . 7 . Ability understand sign PreScreening Consent Form . 8 . Patients willing test transmissible disease ( active Hepatitis B ( HBV ) Hepatitis C ( HCV ) , human immunodeficiency virus ( HIV ) , Human TCell Lymphotropic Virus ( HTLV ) , Herpes Simplex Virus ( HSV ) , Cytomegalovirus ( CMV ) , Syphilis ( West Nile Virus test May 1st November 30th ) 9 . Confirmation Translational Immunotherapy Lab able process specimen 10 . If history allergy penicillin , gentamycin , streptomycin , antifungal , ability generate TILs first confirm cell manufacturing lab ( i.e. , Translational Immunotherapy Laboratory ) . Inclusion Criteria ( Eligibility Treatment ) : 1 . Prior performance studyspecific procedure , subject sign date informed consent form , approve Research Ethics Board ( REB ) , nature study explain subject opportunity ask question . 2 . Recurrent platinum resistant high grade serous ovarian , fallopian tube , primary peritoneal cancer , evidence disease progression previous line treatment . 3 . Measurable disease RECIST 1.1 . 4 . Subjects brain metastasis . Note brain metastasis present , lesion must undergo definitive treatment surgery and/or radiation least 30 day prior first dose lymphodepleting chemotherapy . If opinion PI designee lesion ( ) long represent active disease , subject consider eligible . 5 . Clinical performance status ECOG 0 1 . 6 . Life expectancy &gt; 3 month date consent TIL treatment . 7 . Laboratory analyse tumorinfiltrating lymphocyte ( TILs ) subject must demonstrate TILs suitable use protocol treatment ( perform Translational Immunotherapy Laboratory , Princess Margaret Cancer Centre ) 8 . More 30 day elapse since prior systemic therapy time cell infusion . All subject ' toxicity must recover CTCAE grade 1 le ; however , patient residual CTCAE grade 2 neuropathy previous carboplatin/taxol treatment exclude . Subjects may undergo minor surgical procedure within past 3 week , long toxicity recover CTCAE grade 1 less specify inclusion criterion list . 9 . Adequate organ function define follow criterion : 1 . Serum ALT ≤ 2.5 x upper limit normal ( ULN ) ( patient liver metastasis , serum ALT ≤ 3 x ULN ; 2 . Serum AST ≤ 2.5 x upper limit normal ( ULN ) ( patient liver metastasis , serum AST ≤ 3 x ULN ; 3 . Total serum bilirubin ≤ 2xULN ( patient Gilbert 's Syndrome direct serum bilirubin ≤ 2 x ULN ) ; 4 . Absolute neutrophil count ( ANC ) ≥ 1.5x109/L ; 5 . Platelets ≥100x109/L ; 6 . Hemoglobin ≥ 90 g/L female ; 7 . Alkaline phosphatase ≤ 2 x ULN ; 8 . Serum creatinine within normal institutional limit OR serum creatinine clearance ≥ 60 mL/min/1.73m2 patient creatinine level institutional normal ; 9 . Serum lipase≤ 1.5 x ULN ; 10 . Serum amylase ≤ 1.5 x ULN 10 . Women childbearing potential must negative pregnancy test . Acceptable birth control failure rate le equal 1 % use consistently correctly implant , injectables , combine oral contraceptive , double barrier , intrauterine device ( IUDs ) , sexual abstinence vasectomize partner . Subjects consider child bear potential consider postmenopausal surgically sterilize ( e.g . tubal occlusion , hysterectomy , bilateral salpingectomy . Women amenorrheic 12 month still consider childbearing potential amenorrhea possibly due prior chemotherapy , antiestrogens , ovarian suppression reversible reason . 1 . Subjects ongoing prior use systemic steroid therapy within 4 week TILs infusion exclude . Use topical , intranasal inhaled corticosteroid , systemic corticosteroid physiologic dos allow . Oral steroid use premedication prevent allergic reaction radiologic contrast allow . 2 . Subjects HIV positive . 3 . Subjects active hepatitis B hepatitis C , syphilis , Human TCell Lymphotropic Virus ( HTLV ) . 4 . The number prior line chemotherapy limit . However , subject ≥3 line prior chemotherapy platinum refractory platinum resistant disease , documentation response one line require . Response define RECIST 1.1 CA125 define modify GCIG criterion ( See Section 11 ) . 5 . The subject active systemic infection , coagulation disorder active major medical illness cardiovascular , respiratory immune system , uncontrolled psychiatric disorder , condition may affect compliance trial . 6 . The subject must active underlying cardiac illness define positive stress test , LVEF &lt; 40 % ongoing lifethreatening arrhythmia ( i.e. , patient older 60 year age otherwise clinically indicate ) . 7 . Subjects prolong history cigarette smoking symptom respiratory dysfunction exclude abnormal pulmonary function test evidence FEV1 &lt; 60 % predict .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Measurable</keyword>
	<keyword>Recurrent</keyword>
	<keyword>Platinum resistant</keyword>
	<keyword>Tumor-Infiltrating Lymphocytes</keyword>
	<keyword>Low-Dose Interleukin-2</keyword>
	<keyword>Autologous dendritic cell</keyword>
	<keyword>Anti-CD3 monoclonal antibody</keyword>
	<keyword>High grade serous ovarian , fallopian tube , primary peritoneal cancer</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>